Interim data monitoring to enroll higher-risk participants in HIV prevention trials by Halpern, Vera et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Medical Research 
Methodology
Open Access Research article
Interim data monitoring to enroll higher-risk participants in HIV 
prevention trials
Vera Halpern*1, Orikomaba Obunge2, Folasade Ogunsola3, 
Sakiru Otusanya3, John Umo-Otong2, Chin-Hua Wang1 and Neha Mehta1
Address: 1Family Health International, Research Triangle Park, NC, USA, 2Department of Medical Microbiology and Parasitology, University of 
Port Harcourt Teaching Hospital, Port Harcourt, Nigeria and 3Department of Medical Microbiology and Parasitology, College of Medicine, 
University of Lagos, Lagos, Nigeria
Email: Vera Halpern* - vhalpern@fhi.org; Orikomaba Obunge - ik_obunge@yahoo.com; Folasade Ogunsola - sade.ogunsola@gmail.com; 
Sakiru Otusanya - otudupsy@yahoo.co.uk; John Umo-Otong - johnumotong@yahoo.com; Chin-Hua Wang - lily_wang@unc.edu; 
Neha Mehta - NMehta@pozen.com
* Corresponding author    
Abstract
Background: Lower-than-expected incidence of HIV undermines sample size calculations and
compromises the power of a HIV prevention trial. We evaluated the effectiveness of interim
monitoring of HIV infection rates and on-going modification of recruitment strategies to enroll
women at higher risk of HIV in the Cellulose Sulfate Phase III study in Nigeria.
Methods: We analyzed prevalence and incidence of HIV and other sexually transmitted infections,
demographic and sexual behavior characteristics aggregated over the treatment groups on a
quarterly basis. The site investigators were advised on their recruitment strategies based on the
findings of the interim analyses.
Results: A total of 3619 women were screened and 1644 enrolled at the Ikeja and Apapa clinics
in Lagos, and at the Central and Peripheral clinics in Port Harcourt. Twelve months after study
initiation, the overall incidence of HIV was less than one-third of the pre-study assumption, with
rates of HIV that varied substantially between clinics. Due to the low prevalence and incidence
rates of HIV, it was decided to close the Ikeja clinic in Lagos and to find new catchment areas in
Port Harcourt. This strategy was associated with an almost two-fold increase in observed HIV
incidence during the second year of the study.
Conclusion:  Given the difficulties in estimating HIV incidence, a close monitoring of HIV
prevalence and incidence rates during a trial is warranted. The on-going modification of
recruitment strategies based on the regular analysis of HIV rates appeared to be an efficient method
for targeting populations at greatest risk of HIV infection and increasing study power in the Nigeria
trial.
Trial Registration: The trial was registered with the ClinicalTrials.gov registry under
#NCT00120770 http://clinicaltrials.gov/ct2/show/NCT00120770
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Background
Lower-than-expected incidence of HIV in a HIV preven-
tion trial may undermine sample size calculations and
compromise study power [1]. Even if the study commu-
nity has been well characterized before the trial, the study
population will be a selected sub-sample of that commu-
nity, which may have lower incidence. Furthermore, ethi-
cally warranted risk reduction procedures may lead to
behavioral changes and increased condom use and thus,
lower risk of HIV among the study cohort. This phenom-
enon, although based on self-reports, has been noted in
several trials [2,3].
We conducted a trial to evaluate the efficacy of cellulose
sulfate (CS) for preventing HIV in Nigeria. In designing
our trial, we based our estimate of HIV incidence on the
national HIV prevalence in Nigeria reported two years
before study initiation [4-6], and on the incidence-to-
prevalence ratio of 2.4 from previous research conducted
by Family Health International (FHI) among similar
study populations in West Africa [7]. Because we were
concerned about the applicability of these data sources to
our specific study population, we planned to monitor the
HIV infection rate quarterly and to adjust recruitment
strategies and sample size in order to protect requisite
study power. Below we describe our methodology and
results.
Methods
We conducted a Phase III, randomized, placebo-control-
led trial in Lagos and Port Harcourt, Nigeria between
November 2004 and March 2007. Three Institutional
Review Boards approved the study: those of the College of
Medicine, University of Lagos; the University of Port Har-
court Teaching Hospital; and Family Health International.
All participants signed written informed consent forms
before enrollment. The study was monitored by a Data
Monitoring Committee.
Historical data were used to justify our sample size calcu-
lations. Roddy et al. [7] reported a prevalence of HIV of
17% and a subsequent incidence of HIV of 7 per 100
woman-years (WY) among sex workers in Cameroon in
the late 1990's. In urban areas of Nigeria in 2002 the
UNAIDS reported a prevalence of HIV of 5.8% among
pregnant women between the ages of 20 and 24, and of
30.5% among female sex workers [4]. From this we con-
servatively estimated that the prevalence of HIV among
high-risk populations in urban Nigeria should not be
lower than 12% (i.e., at least twice as high as the preva-
lence among the antenatal population). Based on the
prevalence to incidence ratio of 2.4 observed in the Roddy
study, we anticipated an incidence of 5 per 100 WY
among placebo users in our trial. Enrolling 2160 women,
and following each for one year, was expected to achieve
the 66 HIV infections necessary to provide 80% power
detect a halving of the incidence rate among CS users (e.g.
from 5 to 2.5 per 100 WY). Hence, we monitored the
pooled incidence of HIV during the study with the aim of
achieving an overall rate of 3.75 per 100 WY.
The admission criteria and study procedures for this study
have been described elsewhere [8]. Briefly, a total of 3619
women were screened and 1644 enrolled into the CS trial
at the Ikeja and Apapa clinics in Lagos, and at the Central
and Peripheral clinics in Port Harcourt. The Ikeja and
Apapa clinics screened 598 and 1371, respectively, and
enrolled 279 and 584 women into the study. The Central
and Peripheral clinics screened 1044 and 605, respec-
tively, and enrolled 518 and 262 women into the study.
All enrolled women were at high risk of HIV acquisition,
meaning that they reported three or more acts of inter-
course per week and more than one sexual partner in the
last three months. Most study participants were low-
income women who exchanged sex for money to supple-
ment their incomes, although most did not identify them-
selves as sex workers. We did not exclude professional sex
workers from the trial but intentionally limited their
number due to the concerns associated with their high
coital frequency and its potential impact on gel compli-
ance. Participants were randomized to use CS gel and con-
doms or placebo gel and condoms for all acts of sexual
intercourse throughout the 12 months of study participa-
tion. During monthly follow-up visits the participants
were tested for HIV, gonorrhea and chlamydial infection.
Study data were collected at the sites and entered by local
staff into FHI's database. Blinded datasets were used to
assess recruitment strategies one year after study initiation
and quarterly, thereafter. We assessed the following
parameters, aggregated over the treatment groups:
number of screened and enrolled participants, prevalence
and incidence of HIV and other sexually transmitted infec-
tions (STIs) (by month and overall), demographic charac-
teristics and self-reported sexual behavior. HIV/STI
prevalence was defined as a proportion of infected partic-
ipants among women screened for the study. HIV/STI
incidence was defined as the rate of new infections in the
study. The site investigators were advised on their recruit-
ment strategies based on the findings of the interim anal-
yses.
Results
A total of four such interim analyses were conducted
between the initiation of the study in November 2004 and
its closure in January 2007: on January 17, 2006 (i.e.
approximately one year after study initiation); May 02,
2006; July 31, 2006; and November 21, 2006. The first
review demonstrated that the overall incidence of HIV was
less than one-third of the pre-study estimate (Figure 1),BMC Medical Research Methodology 2009, 9:44 http://www.biomedcentral.com/1471-2288/9/44
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with only one clinic (the Apapa clinic in Lagos) reporting
near the expected rate of 3.4 per 100 WY (Figure 2 and 3).
We noted that although HIV prevalence at screening was
highest at the Apapa clinic, women screened at that site
had substantially lower coital frequency, fewer partners,
and fewer acts unprotected by condoms than women
screened at either of the two Port Harcourt clinics, where
HIV prevalence was lower (Table 1). We observed a simi-
lar inverse association between the prevalence of gonor-
rhea at screening and self-reported measures of high risk
sexual activity. Further, both the HIV prevalence and the
sexual activity level in the screened population were low-
est at the Ikeja clinic.
The most noticeable differences in demographic charac-
teristics were that women in the Apapa clinic were slightly
younger and less educated than those in Ikeja and the two
Port Harcourt clinics (Table 2).
Based on the observations at the first interim analysis, we
stopped recruiting at Ikeja because of the comparatively
low prevalence of HIV and lack of any incident cases dur-
ing the first year of the study. Similarly, efforts of the
recruitment team in Port Harcourt were concentrated on
identifying new catchment areas with populations at
higher risk of HIV.
Subsequent quarterly analyses showed that HIV preva-
lence remained relatively high in the Apapa clinic and the
two clinics in Port Harcourt, ranging between 14% and
20%. The observed incidence in Lagos decreased slightly
between January 2006 and November 2006, even after
dropping the Ikeja clinic (Figure 2). The observed HIV
incidence in Port Harcourt more than doubled during the
same period, however (Figure 3). Seemingly as a result of
the changes in recruitment efforts, the overall incidence of
HIV in the study increased from 1.0 per 100 WY in January
2006 to 1.8 per 100 WY in November 2006 (Figure 1).
Nonetheless, the incidence was noticeably lower than
expected when designing the trial, leading the study team
to stop enrollment in Nigeria and to expand the trial to
South Africa, a country with a much higher background
HIV incidence. However, the sites in South Africa never
started recruitment because of the premature termination
of the study on 31 January 2007 due to safety concerns
raised in a parallel CS trial [9].
Discussion
Accurate incidence estimates are required to make
informed sample size and power calculations. The best
method of collecting incidence data is to conduct prospec-
tive research on large cohorts [10,11]. Such studies are
capable of simulating a trial setting, but are time-consum-
ing and extremely expensive. In addition, there is no guar-
antee that incidence will be maintained once the actual
Incidence of HIV in Nigeria, by site and overall Figure 1
Incidence of HIV in Nigeria, by site and overall.
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Incidence of HIV in Lagos, by clinic and overall Figure 2
Incidence of HIV in Lagos, by clinic and overall.
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trial starts. As an alternative, laboratory assays can distin-
guish recent from long-term HIV-1 infections in cross-sec-
tional survey [12]. While this method is quick and
inexpensive, it does not simulate a trial setting in terms of
recruitment, follow-up, or intervention, and its accuracy
has been questioned [13].
Many first-generation HIV prevention trials relied on
available country-specific HIV prevalence data and HIV
prevalence-incidence ratio from previous trials [2,3,14].
In our study in Nigeria, we estimated that the incidence of
HIV should not be lower than 5 per 100 WY in the control
arm, and 3.75 per 100 WY overall if the product was 50%
effective. Although we considered these assumptions con-
servative, the trial proved otherwise. The on-going moni-
toring of the HIV data showed that while most of the
clinics reported the expected prevalence of 12% or higher,
only one out of four reported an infection rate higher than
3.0 per 100 WY, with an overall incidence of 1.8 per 100
WY.
Our  a priori data monitoring plan led us to calculate
interim incidence rates on a quarterly basis and modify
our recruitment strategies accordingly in order to increase
the likelihood of enrolling high-risk populations and
achieve the target number of events within a reasonable
timeframe. The closure of the Ikeja clinic in Lagos and
inclusion of new catchment areas in Port Harcourt was
associated with an almost two-fold increase of the HIV
incidence during the second year of the trial. As a direct
result of our efforts we identified pockets of acute HIV
transmission and populations at very high risk of HIV in
two large cities in Nigeria. For comparison, Padian et al.
reported an HIV incidence of 2.7 per 100 WY in Zimba-
bwe [15], a country where the HIV epidemic is more gen-
eralized and national adult HIV prevalence exceeds 15%
[16].
Unfortunately, slow enrollment and poor study retention
were downsides of our recruitment efforts in Nigeria. It
took almost two years to accomplish 75% of the targeted
enrollment, instead of the one year originally planned.
About one third of the study participants were lost. The
participants in the Apapa clinic who were at highest risk of
HIV, consistently reported the highest rates of loss to fol-
low-up and missed visits during the study (data not
shown). The observed correlation between risk of HIV and
study retention suggested that demographics played a
major role in loss to follow-up. We compromised our
retention rates by recruiting young women at highest risk
of HIV infection, residential mobility, and poor compli-
ance with the protocol procedures. While the problem of
Table 1: HIV/STI rates and sexual behavior characteristics by clinic, all women screened (January 2006)
Prevalence/characteristic Apapa Ikeja Central Peripheral
HIV prevalence
(%, 95% CI)*
20.1
(17.2, 23.2)
8.7
(6.5, 11.4)
14.3
(11.9, 16.9)
17.3
(13.8, 21.3)
Gonorrhea prevalence
(%, 95% CI)*
14.9
(12.2, 18.0)
6.7
(4.6, 9.4)
3.4
(2.2, 5.0)
5.5
(3.5, 8.2)
Chlamydia prevalence
(%, 95% CI)*
5.4
(3.7, 7.5)
5.3
(3.4, 7.7)
2.9
(1.8, 4.3)
2.2
(1.0, 4.2)
Average number of coital acts in last week 3.9 2.8 7.1 5.6
Average number of new partners in last month 1.8 0.4 8.2 5.1
Proportion of coital acts protected by condom in last week (%) 66.7 52.0 55.2 59.3
*cumulative (i.e., proportion of infections among all participants screened into the study by January 2006)
Table 2: Selected demographic characteristics by clinic, all women screened (January 2006)
Characteristics (%) Apapa Ikeja Central Peripheral
Age < 25 years 72.9 66.7 71.8 70.6
Years of school <= 12 96.7 87.4 62.7 57.7
Current occupation: student 9.3 23.0 36.4 29.0BMC Medical Research Methodology 2009, 9:44 http://www.biomedcentral.com/1471-2288/9/44
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lower-than-expected incidence can be solved, among
other means, by increasing sample size without threaten-
ing validity of the results, the consequences of poor reten-
tion on interpretation of the data are difficult to
overcome. Difficult and prolonged enrollment as well as
potential detriment to study retention are serious limita-
tions of conducting a prevention trial among high-risk
populations in a low-prevalence country and should be
taken into careful consideration before choosing a coun-
try and/or site for future HIV-prevention trials.
The observed inverse association between the prevalence
of HIV and self-reported measures of sexual activity
among the two clinics in Port Harcourt and the Apapa
clinic in Lagos could have several explanations. Addi-
tional information collected informally by the site inves-
tigators in Port Harcourt suggested that recruitment in
brothel-like structures and hotels, in many of which the
use of condoms was mandatory, was one possible reason
for the low HIV rates despite high sexual activity at this
site. Seemingly, women in these hotels practiced safe sex
and, as a result, were not at high risk of HIV in spite of
their high level of sexual activity. However, the self-
reported data on condom use does not support this spec-
ulation (Table 1). Another possible explanation is that the
level of the HIV epidemic in Port Harcourt in general was
lower than in the Apapa area in Lagos.
While the interim data monitoring and on-going modifi-
cation of recruitment strategies appeared to be successful
in increasing the overall incidence of HIV, the early clo-
sure of the CS trial in Nigeria limited our ability to thor-
oughly evaluate the effectiveness of this approach.
Clearly, the closure of the Ikeja clinic in Lagos was the sin-
gle most important contributing factor in the increase of
the observed overall HIV incidence. The effect would have
been more profound if this decision had been made
sooner. At the same time it is unclear to what extent the
modification of recruitment strategies in Port Harcourt
contributed to the increase of the observed overall HIV
incidence, or if it would have resulted in further substan-
tial increase if the trial had continued as planned.
Conclusion
In planning future HIV prevention trials, researchers
should use all available means of accurate incidence esti-
mation and, if possible, measurement of HIV incidence in
a potential study population. However, given the limita-
tions of the existing methods, a close monitoring of HIV
prevalence and incidence rates during the trial seems pru-
dent. The on-going modification of recruitment strategies
based on the regular analysis of HIV rates, although not
without limitations, appeared to be an efficient method
for targeting populations at greatest risk of HIV infection
in Nigeria. Direct access to study data and early initiation
of regular interim monitoring are important for produc-
ing measurable results within a limited time frame.
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